Psoriasis

The use of biologic therapy to treat psoriasis and psoriatic arthritis has increased over time along with the use of systemic corticosteroids, according to a letter published in the Journal of the American Academy of Dermatology.

A growing body of evidence is emerging in support of medical nutrition therapy as a way of reducing severity and incidence of dermatologic diseases, according to recent findings.

MAUI, HAWAII — Though approximately 25% of patients with psoriasis will eventually develop psoriatic arthritis, it remains unclear which patients will, according to a presentation here at Maui Derm for Dermatologists 2020.

MAUI, HAWAII — Several different psoriasis treatments, including those that would provide much needed relief for pediatric patients, are currently making their way through the product pipeline, two panelists at Maui Derm for Dermatologists 2020 said.

MAUI, HAWAII — A novel study that examined the link between psoriasis and CVD was one of several studies summarized at Maui Derm for Dermatologists 2020 that examined psoriasis’ link to several co-morbidities.

Some 500 dermatologists will gather in Maui at the end of January for the sixth annual Maui Derm for Dermatologists meeting. If all goes as planned, they will leave the Hawaiian island with actionable strategies to put to immediate use in the clinic.

Both ixekizumab and brodalumab were associated with better clinical benefit than other biologic therapies over 12 weeks or 16 weeks of treatment for psoriasis, according to a meta-analysis.

Although TNF inhibitor use was associated with an increased risk of serious infection among patients with psoriasis and self-reported psoriatic arthritis, recent data published in BMC Rheumatology found these differences were not statistically significant.

Patients with hepatitis B and C virus infections should be screened for risk before receiving antipsoriatic therapy, according to a study published by the American Journal of Clinical Dermatology.

Patients with inflammatory bowel disease and other immune-mediate diseases treated with anti-TNF alpha who previously had cancer are not at greater risk for recurrent or new primary cancers, according to the results of a population-based study.